...
机译:用AXL抗体 - 药物缀合物和BRAF / MEK抑制剂的黑色素瘤异质性的协同靶向
Netherlands Canc Inst Oncode Inst Div Mol Oncol &
Immunol Amsterdam Netherlands;
Genmab Utrecht Netherlands;
Netherlands Canc Inst Oncode Inst Div Mol Oncol &
Immunol Amsterdam Netherlands;
Netherlands Canc Inst Oncode Inst Div Mol Oncol &
Immunol Amsterdam Netherlands;
Genmab Utrecht Netherlands;
Netherlands Canc Inst Oncode Inst Div Mol Oncol &
Immunol Amsterdam Netherlands;
Netherlands Canc Inst Oncode Inst Div Mol Oncol &
Immunol Amsterdam Netherlands;
Netherlands Canc Inst Oncode Inst Div Mol Oncol &
Immunol Amsterdam Netherlands;
Netherlands Canc Inst Oncode Inst Div Mol Oncol &
Immunol Amsterdam Netherlands;
Netherlands Canc Inst Div Expt Anim Pathol Amsterdam Netherlands;
Genmab Utrecht Netherlands;
Genmab Utrecht Netherlands;
Netherlands Canc Inst Oncode Inst Div Mol Oncol &
Immunol Amsterdam Netherlands;
Netherlands Canc Inst Oncode Inst Div Mol Oncol &
Immunol Amsterdam Netherlands;
Netherlands Canc Inst Oncode Inst Div Mol Oncol &
Immunol Amsterdam Netherlands;
Genmab Utrecht Netherlands;
Genmab Utrecht Netherlands;
Genmab Utrecht Netherlands;
Netherlands Canc Inst Oncode Inst Div Mol Oncol &
Immunol Amsterdam Netherlands;
Genmab Utrecht Netherlands;
机译:用AXL抗体 - 药物缀合物和BRAF / MEK抑制剂的黑色素瘤异质性的协同靶向
机译:MAPK通路抑制剂使BRAF突变型黑素瘤对靶向GPNMB的抗体药物偶联物敏感
机译:对Ipilimumab / Nivolumab重新检查和BRAF抑制剂/ MEK抑制剂在患者中重新检查,所述患者预先用BRAF靶向治疗和免疫治疗治疗
机译:疏水相互作用色谱分离半胱氨酸 - 共轭抗体 - 药物缀合物异质性的分离与表征
机译:优化NRAS突变体黑素瘤耐久性和组合策略中的MEK抑制剂
机译:MAPK途径抑制剂可将BRAF突变性黑素瘤对靶向GPNMB的抗体-药物偶联物敏感
机译:靶向BRD / BET蛋白抑制适应性的Kinome上调,并增强BRAF / MEK抑制剂在黑色素瘤中的影响